LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Verve Therapeutics Inc

Cerrado

11.3 0.53

Resumen

Variación precio

24h

Actual

Mínimo

11.24

Máximo

11.31

Métricas clave

By Trading Economics

Ingresos

19M

-31M

Ventas

20M

33M

BPA

-0.35

Margen de beneficio

-94.108

Empleados

274

EBITDA

19M

-35M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+34.34% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

604M

992M

Apertura anterior

10.77

Cierre anterior

11.3

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Verve Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 jun 2025, 11:56 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

17 jun 2025, 14:02 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17 jun 2025, 12:12 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17 jun 2025, 11:01 UTC

Adquisiciones, fusiones, absorciones

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17 jun 2025, 10:47 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17 jun 2025, 10:47 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17 jun 2025, 10:46 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17 jun 2025, 10:45 UTC

Adquisiciones, fusiones, absorciones

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17 jun 2025, 09:33 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

Comparación entre iguales

Cambio de precio

Verve Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

34.34% repunte

Estimación a 12 meses

Media 15.06 USD  34.34%

Máximo 24 USD

Mínimo 11 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Verve Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

4

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

4.1501 / 5.16Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.